Response Biomedical (RPBIF) 10-Q 8 May 15 2015 Q1 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	3 Months Ended
	Mar. 31, 2015	1-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	RESPONSE BIOMEDICAL CORP
Document Type	10-Q
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		9,874,538
Amendment Flag	FALSE
Entity Central Index Key	806888
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (CAD)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Current
Cash and cash equivalents	1,439		3,221
Trade receivables, net	1,706		702
Other receivables	166		89
Inventories [note 5]	2,499		2,056
Prepaid expenses and other	301		183
Deferred debt financing costs - current portion	77		88
Total current assets	6,188		6,339
Deferred financing costs	30		45
Long-term prepaid expenses	93		93
Restricted deposits [note 8]	901		901
Property, plant and equipment	6,392		6,250
Total assets	13,604		13,628
Current
Accounts payable and accrued liabilities [note 6]	4,665		3,867
Term loan - current portion [note 7]	750		494
Lease inducements - current portion [note 8]	169		169
Repayable leasehold improvement allowance - current portion [note 8]	474	[1]	461	[1]
Deferred revenue	1,083		873
Warrant liability [notes 4 and 9]	1,194		1,249
Total current liabilities	8,335		7,113
Lease inducements [note 8]	1,154		1,197
Term loan	910		1,004
Repayable leasehold improvement allowance [note 8]	5,085		5,208
	15,484		14,522
Commitments [note 11]	0		0
Shareholders' deficit
Common shares [note 9]	104,270		104,124
Additional paid-in capital [note 9]	15,209		15,241
Deficit	-121,359		-120,259
Total shareholders' deficit	-1,880		-894
	13,604		13,628
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three month period ended March 31, 2015 amounted to $110,000 [2014 - $89,000]. Interest payments for the three month period ended March 31, 2015 amounted to $155,000 [2014 - $176,000].

Consolidated_Statements_of_Los

Consolidated Statements of Loss and Comprehensive Loss (Unaudited) (CAD)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
REVENUE
Product sales [note 12]	3,271	2,559
Collaborative revenue [note 10]	269
Total revenue	3,540	2,559
Cost of sales [notes 5, 9, and 11]	2,176	1,440
Gross profit	1,364	1,119
EXPENSES [notes 9 and 11]
Research and development	813	811
General and administrative	675	811
Sales and marketing	664	646
Total operating expenses	2,152	2,268
OTHER EXPENSES (INCOME)
Interest expense and amortization of deferred financing costs and debt discounts [note 7]	235	197
Interest income	-3	-5
Other expense	22	17
Foreign exchange loss	113	4
Unrealized (gain) loss on revaluation of warrant liability [note 4]	-55	161
Total other expenses	312	374
Net loss and comprehensive loss for the period	-1,100	-1,523
Loss per common share - basic and diluted[note 9] (in Dollars per share)	-0.11	-0.19
Weighted average number of common shares outstanding - basic and diluted [note 9] (in Shares)	9,774,890	7,880,542

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Deficit (Unaudited) (CAD)	Private Placement [Member]	Private Placement [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
In Thousands, except Share data	Common Stock [Member]
Balance at Dec. 31, 2013			101,945	14,742	-118,169	-1,482
Balance (in Shares) at Dec. 31, 2013			7,870,925
Net loss					-2,090	-2,090
Private placement, net of issue costs	2,024	2,024
Private placement, net of issue costs (in Shares)	1,800,000
Net shares issued upon conversion of restricted share units			155	-155
Net shares issued upon conversion of restricted share units (in Shares)			88,635
Net warrants issued per terms of loan				113		113
Stock-based compensation expense				381		381
Restricted share units				160		160
Balance at Dec. 31, 2014			104,124	15,241	-120,259	-894
Balance (in Shares) at Dec. 31, 2014			9,759,560
Net loss					-1,100	-1,100
Net shares issued upon conversion of restricted share units			146	-146
Net shares issued upon conversion of restricted share units (in Shares)			114,978
Stock-based compensation expense				55		55
Restricted share units				59		59
Balance at Mar. 31, 2015			104,270	15,209	-121,359	-1,880
Balance (in Shares) at Mar. 31, 2015			9,874,538

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (Unaudited) (CAD)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Net loss for the period	-1,100	-1,523
Add (deduct) items not involving cash:
Depreciation of property, plant and equipment	253	243
Amortization of deferred lease inducements	-43	-43
Amortization of deferred financing costs	26	13
Amortization of discount on debt	15	5
Stock-based compensation	55	151
Unrealized loss (gain) on revaluation of warrant liability	-55	161
Other non-cash items	147	-2
Changes in non-cash working capital:
Trade receivables	-1,004	472
Other receivables	-77	62
Inventories	-443	-114
Prepaid expenses and other	-118	-49
Accounts payable and accrued liabilities	807	248
Deferred revenue	210	104
Cash used in operating activities	-1,327	-272
INVESTING ACTIVITIES
Purchase of property, plant and equipment	-345	-94
Cash used in investing activities	-345	-94
FINANCING ACTIVITIES
Repayment of repayable leasehold improvement allowance	-110	-99
Proceeds from term loan		1,661
Debt financing cost		-105
Cash provided by (used in) financing activities	-110	1,457
Increase (decrease) in cash during the period	-1,782	1,091
Cash and cash equivalents, beginning of period	3,221	2,958
Cash and cash equivalents, end of period	1,439	4,049

Note_1_Description_of_Business

Note 1 - Description of Business	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Business Description and Basis of Presentation [Text Block]	1.     DESCRIPTION OF BUSINESS
	Response Biomedical Corp. (“Response” or the “Company”) was incorporated on August 20, 1980 under the predecessor to the Business Corporations Act (British Columbia). The Company’s wholly owned US subsidiary, Response Point of Care Inc., was incorporated on November 9, 2012 in the State of Delaware. The Company is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical point of care (POC), laboratory and on-site environmental testing markets. POC and on-site diagnostic tests (or assays) are simple, non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks. Since 1996, the Company has developed and commercialized a proprietary diagnostic system called RAMP®.
	The RAMP® System is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test, establishing a new paradigm in diagnostic testing. Immunoassays are extremely sensitive and specific tests used to identify and measure small quantities of materials, such as proteins. A large variety of biological molecules and inorganic materials can be targeted. Accordingly, the RAMP® technology is applicable to multiple distinct market segments and many products within those segments. RAMP® tests are now commercially available for use in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, environmental detection of West Nile Virus antigen, and biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Note_2_Basis_of_Presentation_a

Note 2 - Basis of Presentation and Going Concern Uncertainty	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	2.     BASIS OF PRESENTATION AND GOING CONCERN UNCERTAINTY
	These unaudited interim consolidated financial statements have been prepared by management in Canadian dollars in accordance with United States generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required to be presented for complete financial statements. The accompanying unaudited consolidated financial statements reflect, in the opinion of management, all adjustments (which include reclassifications and normal recurring adjustments) necessary for a fair presentation of the results for the interim periods presented. The accompanying consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year then ended. The consolidated financial statements and related disclosures have been prepared with the assumption that users of the interim financial information have read or have access to the audited consolidated financial statements for the preceding fiscal year. Accordingly, these unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2014 and filed with the United States Securities and Exchange Commission (“SEC”) on March 19, 2015.
	Going Concern Uncertainty
	The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and liabilities and commitments in the normal course of business.
	During the quarter ended March 31, 2015, the Company has incurred a net loss of $1.1 million and negative cash flows from operations of $1.3 million. As of March 31, 2015, the Company had a cash balance of $1.4 million, an accumulated deficit of $121.4 million, a shareholders’ deficit of $1.9 million, and a negative working capital balance of $2.1 million. In addition, the Company has various operating leases and purchase commitments for inventory (refer to note 11). Included in current liabilities is a warrant liability in the amount of $1.2 million that is required to be measured at fair value. The potential settlement of these warrants would not have a cash impact as they may only be exercised on a net cashless basis. Without taking into account the warrant liability mentioned above, current liabilities exceed current assets by $951,000.
	The ability of the Company to continue as a going concern is uncertain and dependent on the Company’s ability to obtain additional financing and/or achieve cash flow positive operations. Management has, thus far, financed the operations through a series of equity financings, debt financing, and collaborative arrangements. On October 15, 2014, the Company entered into a funded Technology Development Agreement and on February 16, 2015, a Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. (“Joinstar”) to support the co-development by Response and Joinstar of components and multiple assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Under the terms of the agreements, Response has received milestones totaling US$1.64 million to date and is eligible to receive a further US$2.16 million in development milestones over the remaining planned twelve month project period. In conjunction with the signing of the Collaborative Agreement, Response and Joinstar entered into a definitive Supply Agreement whereby Response will provide certain materials required for Joinstar to manufacture and sell the developed assays specifically to run on their analyzer. Under the terms of the Supply Agreement, Response is eligible to receive a guaranteed US$2.13 million in revenue-based payments over the first five years of commercialization of the co-developed assays.
	In addition to the Joinstar agreements, on February 11, 2014, the Company secured a US$2.5 million term loan from Silicon Valley Bank (“SVB”) of which only US$1.5 million was drawn down. On December 15, 2014, Response announced that it had entered into an amendment to the original term loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate, waive its rights in respect of previous breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. In addition, SVB received additional warrants and will receive a final payment of up to 4% of the principal advanced. Refer to note 7 for the significant terms to the loan.
	Management believes that, with the targeted execution under the Joinstar Agreements, based on the current level of operations and excluding out of the ordinary cash management measures, the Company’s cash and cash equivalent balances, including cash generated from operations, will be sufficient to meet the anticipated cash requirements through the next twelve months. However, due to the Company’s history of losses, there is substantial doubt over the Company’s ability to continue as a going concern as it is dependent on meeting the development milestones required to earn the additional US$2.16 million in development fees under the Collaboration Agreement with Joinstar or achieving profitable operations, the outcomes of which cannot be predicted at this time. The consolidated financial statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.

Note_3_Recent_Accounting_Prono

Note 3 - Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	3.     RECENT ACCOUNTING PRONOUNCEMENTS
	Accounting Pronouncements Not Yet Adopted
	In May 2014, the FASB issued Accounting Standard Update ("ASU") 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This pronouncement is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.
	In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 2015-40) (“ASU 2014-15”). ASU 2014-15 provides guidance to U.S. GAAP about management’s responsibility to evaluate whether there is a substantial doubt about an entity’s ability to continue as a going concern and to provide related footnote disclosures. This new rule requires management to assess an entity’s ability to continue as a going concern by incorporating and expanding upon certain principles currently in the U.S. auditing standards. Specifically, ASU 2014-15 (1) defines the term substantial doubt, (2) requires an evaluation of every reporting period including interim periods, (3) provides principles for considering the mitigating effect of management’s plans, (4) requires an express statement and other disclosures when substantial doubt is not alleviated, and (5) requires an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). This guidance is effective for annual periods ending after December 15, 2016. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures.
	In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20) (“ASU 2015-01”). ASU 2015-01 changed the requirements for reporting extraordinary and unusual items in the income statement. The update eliminates the concept of extraordinary items. The presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring. A reporting entity may apply the amendments prospectively or retrospectively to all periods presented in the financial statements. The guidance will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The adoption of this newly issued guidance is not expected to have an impact to our consolidated financial statements.
	In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810), Amendments to the Consolidation Analysis (“ASU 2015-02). ASU 2015-02 affected current consolidation guidance. The guidance changes the analysis that a reporting entity must perform to determine whether it should consolidate certain types of legal entities. This guidance must be applied using one of two retrospective application methods and will be effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in any interim period. The Company is currently evaluating the impact, if any, of the adoption of this newly issued guidance to our consolidated financial statements.
	In April 2015, the FASB issued ASU 2015-03, Interest-Imputation of Interest (Subtopic 835-30) (“ASU 2015-03”). ASU 2015-03 was issued to simplify the presentation of debt issuance costs. The guidance requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. This guidance should be applied on a retrospective basis, wherein the balance sheet of each individual period presented should be adjusted to reflect the period-specific effects of applying the new guidance. The guidance will be effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early adoption is permitted for financial statements that have not been previously issued. We are currently evaluating the impact, if any, of the adoption of this newly issued guidance to our consolidated financial statements.

Note_4_Fair_Value_Measurements

Note 4 - Fair Value Measurements

3 Months Ended

Mar. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

4.     FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (“exit price”) in an orderly transaction between market participants at the measurement date. Fair value measurements of financial instruments are determined by using a fair value hierarchy that prioritizes the inputs to valuation techniques into three levels according to the relative reliability of the inputs used to estimate the fair values.

The three levels of inputs used to measure fair value are as follows:

Level 1 – Unadjusted quoted prices in active markets for identical financial instruments;

Level 2 – Inputs other than quoted prices that are observable for the financial instrument either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

In determining fair value measurements, the Company uses the most observable inputs when available.

For certain of the Company’s financial instruments, including cash and cash equivalents, trade receivables, other receivables, and accounts payable and accrued liabilities the carrying amounts approximate fair values due to their short-term nature. The carrying value of the restricted deposits approximates its fair value due to the nature of the cash deposit. The fair value of the term loan approximates its carrying value as the term loan with SVB was secured during the first quarter of 2014 and renegotiated in the fourth quarter of 2014 and therefore approximates the current market rate for the term loan. The fair value of the repayable leasehold improvement allowance approximates its carrying value as the fixed interest rate of 11% is considered to approximate the current market rate.

The fair value hierarchy level at which a financial instrument is categorized is determined on the basis of the lowest level input that is significant to the fair value measurement (in thousands):

Financial Instruments carried at fair value as of March 31, 2015

Level 1

Level 2

Level 3

Total

Liabilities

$

$

$

$

Warrant Liability

-

-

1,194

1,194

As of March 31, 2015, the warrant liability is recorded at its fair value of $1.2 million. The Company reassesses the fair value of the common stock warrants at each reporting date utilizing a Black-Scholes pricing model. Inputs used in the pricing model include estimates of stock price volatility, contractual term of the warrant, and risk-free interest rate (refer to note 9[g]). The computation of expected volatility was based on the historical volatility of the Company’s stock. A small change in the estimates used in the Black-Scholes pricing model may have a relatively large change in the estimated valuation of the common stock warrants.

The following table presents the changes in fair value of the Company’s total Level 3 financial liabilities for the three month period ended March 31, 2015 (in thousands):

Balance at

Unrealized loss

Exercise of

Balance at March

31-Dec-14

Warrants

31, 2015

Warrant Liability

$

1,249

$

(55

)

$

-

$

1,194

Quantitative information about unobservable inputs used in Level 3 fair value measurements is presented below:

Valuation

Unobservable Input

As at March 31,

As at December 31,

Technique

2015

2014

Warrant Liability

Option Model

Stock PriceVolatility

102

%

106

%

A 5% increase or decrease in stock price volatility would cause an approximate corresponding $90,000 increase or decrease to the Warrant Liability ($82,000 – December 31, 2014).

Note_5_Inventories

Note 5 - Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5.     INVENTORIES
	Inventories are comprised of the following (in thousands):
		31-Mar-15		31-Dec-14
			$		$
	Raw materials		1,386		1,212
	Work in progress		797		309
	Finished goods		316		535
			2,499		2,056
	The carrying value of inventory as of March 31, 2015 includes a write-down and a provision for expired, obsolete, and damaged inventory in the amount of $129,000 [December 31, 2014 - $135,000]. For the three month period ended March 31, 2015, inventory write-downs and obsolescence charges were $67,000 [2014 - $64,000].

Note_6_Accounts_Payable_and_Ac

Note 6 - Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6.     ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
	Accounts payable and accrued liabilities comprise (in thousands):
		31-Mar-15		31-Dec-14
			$		$
	Trade accounts payable		1,816		1,624
	Employee related accounts payable and accrued liabilities		1,338		1,307
	Royalties		281		287
	Other accrued liabilities		1,230		649
			4,665		3,867
	Accounts payable and accrued liabilities include $65,000 of additions to property, plant, and equipment as at March 31, 2015. This amount has been excluded from cash used in investing activities on the consolidated statements of cash flows for the three months ended March 31, 2015 as the cash had not been disbursed. Consequently, it has also been excluded from cash used in operating activities.

Note_7_Term_Loan

Note 7 - Term Loan	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Long-term Debt [Text Block]	7.     TERM LOAN
	On February 11, 2014, the Company entered into a loan and security agreement with SVB providing for up to a US$2.5 million term loan. The loan is secured by substantially all of the assets of the Company. The loan included financial covenants that were later removed in an amendment (refer to discussion below). The loan also includes certain non-financial covenants as well as a subjective acceleration clause. Under the terms of the original loan agreement, the loan bears an interest rate of Wall Street Journal Prime Rate plus 2.5% annually. Interest only payments were made until October 1, 2014 at which time, 32 equal monthly installments of principal plus accrued interest started to be made. On December 15, 2014, the Company entered into an amendment to the original loan agreement with SVB. Under the amendment, SVB agreed to continue to advance the remaining outstanding principal of US$1.4 million for the same term and interest rate under the original agreement. In addition, SVB waived its rights in respect of certain breaches and removed any future financial covenants. Interest only payments were made until April 1, 2015, at which time, 26 equal monthly installments of principal plus accrued interest are being made through to maturity on May 1, 2017. In addition, the Company will pay an additional final payment of up to 4% of the outstanding principal advanced upon repayment. The loan contains a voluntary prepayment option whereby the principal amount can be prepaid in whole, or in part, for a fixed fee if a prepayment is made on or before February 10, 2016.
	In connection with the original loan and amendment discussed above, 107,701 warrants with exercise prices ranging from $1.00 to $1.831 per warrant and a term of 10 years were granted to SVB. These warrants were measured at their fair market value using the Black-Scholes model on the date of their grants and had a combined estimated fair market value of $113,000 which was recorded as a debt discount that is being amortized into income over the term of the loan using the effective interest method. In addition, there were $233,000 of fees related to the term loan that are also being amortized over the term of the loan using the effective interest method.
	Amortization of the deferred financing costs for the period ended March 31, 2015 was $26,000 (2014 – $13,000) and amortization of the debt discount for the period ended March 31, 2015 was $15,000 (2014 – $5,000). Both of these amounts are included in interest expense and amortization of deferred financing costs and debt discount on the consolidated statements of loss and comprehensive loss.
	The term loan is comprised of the following amounts (in thousands):
		31-Mar-15			31-Dec-14
			$			$
	Current portion of term loan		796			546
	Current portion of unamortized debt discount		(46	)		(52	)
	Current portion of term loan, net of debt discount		750			494
	Long-term portion of term loan		928			1,031
	Long-term portion of unamortized debt discount		(18	)		(27	)
	Long-term of term loan, net of debt discount		910			1,004
	Total		1,660			1,498
	Future principal payments for the term loan as of March 31, 2015, are as follows (in thousands):
	March 31,		$
	2016		796
	2017		796
	2018		132
	2019		-
	2020		-
	Thereafter		-
	Total		1,724

Note_8_Lease_Inducements

Note 8 - Lease Inducements	3 Months Ended
	Mar. 31, 2015
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Other Liabilities Disclosure [Text Block]	8.     LEASE INDUCEMENTS
	Lease agreements entered into by the Company for its offices provides for lease inducements to be provided by the landlord to the Company, which are summarized as follows (in thousands):
		31-Mar-15		31-Dec-14
			$		$
	Current Portion
	Rent-free inducement [i]		54		54
	Non-repayable leasehold improvement allowance [ii]		115		115
			169		169
	Repayable leasehold improvement allowance [iii]		474		461
	Total Current Portion		643		630
	Long-Term Portion
	Rent-free inducement [i]		371		385
	Non-repayable leasehold improvement allowance [ii]		783		812
			1,154		1,197
	Repayable leasehold improvement allowance [iii]		5,085		5,208
	Total Long-Term Portion		6,239		6,405
	Total		6,882		7,035
	The lease inducements disclosed on the consolidated balance sheets as a result of these benefits is comprised of the following:
	[i]     In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three month period ended March 31, 2015 amounted to $14,000 [2014 - $14,000].
	[ii]     The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three month period ended March 31, 2015 amounted to $29,000 [2014 - $29,000].
	[iii]     The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three month period ended March 31, 2015 amounted to $110,000 [2014 - $89,000]. Interest payments for the three month period ended March 31, 2015 amounted to $155,000 [2014 - $176,000].
	To secure the lease, the Company is maintaining a security deposit with the landlord in the form of an irrevocable letter of credit in the amount of $871,000 collateralized by a term deposit with a market value of $871,000 that is presented as part of restricted deposits in the long-term asset section of the balance sheets.

Note_9_Share_Capital_and_Addit

Note 9 - Share Capital and Additional Paid-in Capital	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9.     SHARE CAPITAL AND ADDITIONAL PAID-IN CAPITAL
	[a]     Authorized - Unlimited common shares without par value.
	[b]     Issued
	2014 Private Placement
	On December 12, 2014, the Company closed a private placement with Joinstar related entities consisting of 1,800,000 common shares at a price of $1.21 per share for total gross proceeds of $2,178,000. The net proceeds were $2,024,000 after deduction of $154,000 of financing costs.
	[c]     Stock option plan
	At the Annual General Meeting held September 3, 2008, the Company’s shareholders approved a stock option plan (“2008 Plan”). Under the plan, the Company may grant options to purchase common shares in the Company to employees, directors, officers and consultants of the Company. The exercise price of the options is determined by the Board to be equal to the fair market value of the commons shares on the grant date. The Company estimates the fair value of options on the date of the grant. The options vest over the requisite service period in accordance with terms as determined by the Board, typically over four years. Stock options expire no later than ten years from the date of grant.
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders’ approved a change to the Company’s 2008 stock option plan permitting the maximum shares authorized to be issued under the plan to be up to 20% of the issued and outstanding common shares outstanding at any point in time.
	Of the 1,974,907 stock options authorized for grant under the 2008 Plan as at March 31, 2015, options for 1,052,983 shares were outstanding and 921,924 stock options were available for future grant.
	The following assumptions were used to estimate the fair value of options granted during the three month period ended March 31, 2015, and 2014 using a Black-Scholes option-pricing model:
	Three months ended March 31,		2015			2014
	Risk-free interest rates			0.98	%		2.06	%
	Expected dividend yield			0	%		0	%
	Expected life (in years)			6.1			5.8
	Expected volatility			121	%		126	%
	Fair value per stock option		$	0.8		$	1.31
	The expected volatility reflects the assumption that the historical volatility of common stock of the Company over a period similar to the expected life of the options is indicative of future trends. The Company estimates the risk-free interest rate using the Bank of Canada bond yield with a remaining term equal to the expected life of the option. The Company uses the simplified method for estimating the stock option term for stock option grants during the three month period ended March 31, 2015 as the Company has determined that the stock options are “plain vanilla” and historical share option exercises do not apply as the vesting term and contractual lives have significantly changed from those stock options exercised previously.
	At March 31, 2015, the following stock options were outstanding:
		Range of							Number of		Weighted average		Weighted average		Number of options		Weighted
		exercise price							shares under		remaining		exercise		currently		average exercise
									option		contractual life		price		exercisable		price
		$							#		(years)			$	#			$
		0.88				-	0.92			198,483		9.86		0.91		-		-
		1.02				-	1.60			288,302		8.21		4.46		178,067		1.41
							2.20			388,131		7.03		2.2		355,702		2.2
		3.00				-	3.10			176,243		7.97		3.09		162,375		3.1
		6.80				-	8.20			1,824		0.87		7.7		1,496		7.89
		0.88				-	8.20			1,052,983		8.03		1.91		697,640		2.22
	The options expire at various dates from December 1, 2015 to March 20, 2025.
	Stock option transactions and the number of stock options outstanding are summarized below:
			Number of optioned			Weighted average
			common shares			exercise price
			#				$
	Balance, December 31, 2014			1,007,629			1.99
	Options granted			128,793			0.92
	Options forfeited			(83,439	)		1.33
	Balance, March 31, 2015			1,052,983			1.91
	[d]     Restricted share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new restricted share unit plan (“RSU Plan”). Under the plan, the Company may grant Restricted Share Units (“RSUs”) to employees, directors, and eligible consultants which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of vested RSUs multiplied by the then current market value of the RSUs. The fair market value of the RSUs is determined based upon the number of RSUs granted and the quoted closing price of the Company’s stock on the trading day immediately preceding the date of determination. The duration of the vesting period and other vesting terms applicable to the grant of the RSUs shall be determined by the Board.
			Number			Weighted average
			of RSUs			exercise price
			#				$
	Balance, December 31, 2014			136,348			1.39
	RSUs granted			63,582			0.92
	RSUs converted to common shares			(114,978	)		(1.27	)
	Balance, March 31, 2015			84,952			1.2
	The restricted share units that were granted during the three month period ended March 31, 2015 were to settle a director compensation liability that was recorded in accounts payable and accrued liabilities. The $59,000 liability has been excluded from the change in accounts payable and accrued liabilities on the consolidated statement of cash flows.
	Of the 246,863 RSUs authorized for grant under the RSU Plan as at March 31, 2015, 161,911 RSUs are available for grant.
	[e]     Deferred share unit plan
	At the Annual General and Special Meeting held on June 18, 2013, the Company’s shareholders approved a new non-employee director deferred share unit plan (“DSU Plan”). A Deferred Share Unit (“DSU”) is a right granted to non-employee directors which entitle each participant to either one common share of the Company on a time vested basis or a cash payout equal to the number of DSUs multiplied by the then current market value of the DSUs. The fair market value of the DSU’s is determined based upon the number of DSUs granted and the quoted price of the Company’s stock on the trading day immediately preceding the determination date. The duration of the vesting period and other vesting terms applicable to the grant of the DSU’s shall be determined by the Board.
	Of the 246,863 DSUs authorized for grant under the DSU Plan as at March 31, 2015, all are available for grant.
	[f]     Stock-based compensation
	The following table shows stock-based compensation allocated by type of cost (in thousands):
	Three months ended March 31,		2015			2014
				$			$
	Cost of sales			8			9
	Research and development			11			12
	General and administrative			23			119
	Sales and marketing			13			11
				55			151
	As of March 31, 2015, the total unrecognized compensation related to stock options granted amounts to $483,000, which is expected to be recognized over a weighted average service period of 2.60 years.
	[g]     Common share purchase warrants
	At March 31, 2015, there were 86,865,691 warrants outstanding to purchase shares of common stock, with expiry dates ranging from November 7, 2015 to December 15, 2024. Of the total 86,865,691 warrants outstanding, 86,103,744 warrants (the warrants related to the 2011 financing) entitle the holder thereof to purchase 1/20th of a common share of the Company at a price of $1.492 per whole common share; 636,557 warrants (the private placement warrants) entitle the holder thereof to purchase one common share of the Company at a price of $3.58 per common share; 17,689 warrants (the agent warrants) entitle the holder thereof to purchase one common share of the Company at a price of $2.45 per common share, 52,796 warrants entitle the holder thereof to purchase one common share of the Company at a price of $1.831 per common share, and 54,905 warrants entitle the holder thereof to purchase one common share of the Company at a price of $1.00 per common share.
	There have been no common share purchase warrant transactions during the three months ended March 31, 2015.
The estimated fair value of the warrants related to the 2011 financing is reassessed at each balance sheet date using the Black-Scholes option pricing model. The following assumptions were used to value the warrants on the following balance sheet dates:
As at March 31,		2015			2014
Risk-free interest rates			0.5	%		1.07	%
Expected dividend yield			0	%		0	%
Expected life (in years)			1.75			2.75
Expected volatility			102	%		139	%
Fair value of warrant		$	0.0139		$	0.0629
[h]     Earnings per common share
Basic net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing the net income attributable to common shareholders by the weighted average number of common shares that would have been outstanding during the period assuming the issuance of common shares for all potential dilutive common shares outstanding using the treasury stock method. Dilutive potential common shares outstanding include outstanding warrants, stock options, and restricted share units.
86,865,691 warrants, 1,052,983 stock options and 84,952 restricted share units have been excluded from the computation of diluted earnings per share for the three month period ended March 31, 2015 as the Company has incurred a net loss during the period and their inclusion would be anti-dilutive to the loss per share (2014 – 86,810,786 warrants, 1,487,304 stock options and 48,595 restricted share units were excluded).

Note_10_Related_Party_Transact

Note 10 - Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	10.   RELATED PARTY TRANSACTIONS
	The Company received US$1.28 million from Joinstar upon signing of the Technology Development Agreement and Collaboration Agreement. These upfront payments are being recognized into income over the expected development period and for the three months ended March 31, 2015, $269,000 was recognized (2014 – nil). These development fees are included under collaborative revenue in the consolidated statements of loss and comprehensive loss. The unrecognized portion of the development fees are included, under deferred revenue – current portion, on the consolidated balance sheet.

Note_11_Commitments

Note 11 - Commitments	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block Supplement [Abstract]
Commitments Disclosure [Text Block]	11.   COMMITMENTS
	[a]     License agreements
	The Company entered into a non-exclusive license agreement, effective July 2005, as amended June 2008, to use and sublicense certain technology (“Technology”) for one of the Company’s cardiac tests. In consideration for these rights, the Company paid a non-refundable license issuance fee of $2.0 million in the first two years after execution of the agreement and is required to pay quarterly royalties on the sale of products that incorporate the Technology. For the three month period ended March 31, 2015, the Company incurred an expense of $217,000 [2014 - $117,000] for royalties. Royalty and license fees incurred are included in cost of sales
	[b]     Supply agreement
	The Company entered into a supply agreement, effective September 2003 for certain reagents for the Company’s RAMP® West Nile Virus Test. In addition to paying for the reagent purchased, the Company is required to pay the supplier semi-annual royalties equal to 10% of net revenue generated from the sale of the Company’s RAMP® West Nile Virus Test. The initial term of the agreement was three years from the effective date and is automatically renewed for successive periods of one year until either party terminates the agreement. For the three month period ended March 31, 2015, the Company incurred an expense of $8,000 [2014 – nil] for royalties to the supplier. These royalties are included in cost of sales.
	[c]     Lease agreements
	[i]     The Company entered into a long-term agreement to lease a single tenant 46,000 square foot facility to house all of the Company’s operations. Rent is payable from February 1, 2008 to January 31, 2023. The Company is required to pay the landlord total gross monthly payments of approximately $173,000, which is comprised of base rent, administrative and management fees, estimated property taxes and repayments of the repayable leasehold improvement allowance [note 8[iii]].
	[ii]     The Company entered into a lease agreement for office space for our Shanghai representative office that expires on September 9, 2015. The Company is required to make monthly payments of approximately $8,000 for base rent and management fees under the lease agreement.
	[iii]     The Company has entered into operating leases for administrative equipment.
	For the three month period ended March 31, 2015, $209,000 [2014 - $203,000] was incurred for expenses related to base rent, administrative and management fees and estimated property taxes offset by amortization of both the rent-free inducement [note 8[i]] and non-repayable leasehold improvement allowance [note 8[ii]]. These expenses are allocated to cost of sales, research and development, general and administrative, and sales and marketing expenses.
	[d]     Purchase Commitments
	As at March 31, 2015, the Company has outstanding purchase commitments of $2.9 million to purchase inventory and capital equipment over the next five years of which $2.2 million will be completed during the remaining nine months of 2015.
	[e]     Indemnification of directors and officers
	Under the Articles of the Company, applicable law and agreements with its directors and officers, the Company, in circumstances where the individual has acted legally, honestly and in good faith, may, or is required to indemnify its directors and officers against certain losses.  The Company's liability in respect of the indemnities is not limited. The maximum potential of the future payments is unlimited. However, the Company maintains appropriate liability insurance that limits the exposure and enables the Company to recover any future amounts paid, less any deductible amounts pursuant to the terms of the respective policies, the amounts of which are not considered material.
	[f]     Indemnification of third parties
	The Company has entered into license and research agreements with third parties that include indemnification provisions that are customary in the industry. These indemnifications generally require the Company to compensate the other party for certain damages and costs incurred as a result of third party claims for damages arising from these transactions. The nature of the indemnification obligations prevents the Company from making a reasonable estimate of the maximum potential amount that it could be required to pay. To date, the Company has not made any indemnification payments under such agreements and no amount has been accrued in these consolidated financial statements with respect to these indemnification obligations.

Note_12_Segmented_Information

Note 12 - Segmented Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	12.   SEGMENTED INFORMATION
	The Company operates primarily in one business segment, the research, development, commercialization and distribution of diagnostic technologies, with primarily all of its assets and operations located in Canada. The Company’s revenues are generated from product sales primarily in Asia, the United States, and Europe. Expenses are primarily incurred from purchases made from suppliers in Canada and the United States.
	Customers that represent a concentration risk are those whose outstanding receivable is 10% or greater than the total balance or those customers who represent 10% or greater of our total revenue. For the three month period ended March 31, 2015, $2.4 million (72%) in product sales was generated from one customer [2014 - $1.9 million (74%) from three customers of which one customer represented 40%, one customer represented 19%, and the other customer 14%].
	Product sales by customer location were as follows (in thousands):
	Three months ended March 31,	2015		2014
			$		$
	China		2,378		1,525
	United States		254		210
	Europe		200		428
	Asia (excluding China)		152		155
	Canada		7		4
	Other		280		237
	Total		3,271		2,559
	Product sales by type of product were as follows (in thousands):
	Three months ended March 31,	2015		2014
			$		$
	Cardiovascular		3,089		2,438
	Infectious Diseases		49		69
	Biodefense products		55		44
	West Nile Virus (Environmental)		78		8
	Total		3,271		2,559

Note_13_Comparative_Figures

Note 13 - Comparative Figures	3 Months Ended
	Mar. 31, 2015
Comparative Figures [Abstract]
Comparative Figures [Text Block]	13.   COMPARATIVE FIGURES
	Certain comparative figures have been reclassified from the amounts previously reported to confirm to the presentation adopted in the current year. Taxes paid in China for the representative office previously presented as income taxes have been retroactively reclassified as other expenses.

Note_4_Fair_Value_Measurements1

Note 4 - Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, by Balance Sheet Grouping [Table Text Block]			Level 1				Level 2				Level 3		Total
	Liabilities			$				$				$		$
	Warrant Liability			-				-				1,194		1,194
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]			Balance at				Unrealized loss				Exercise of		Balance at March
			31-Dec-14								Warrants		31, 2015
	Warrant Liability		$	1,249			$	(55	)		$	-	$	1,194
Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]		Valuation	Unobservable Input		As at March 31,				As at December 31,
		Technique			2015				2014
	Warrant Liability	Option Model	Stock PriceVolatility			102	%			106	%

Note_5_Inventories_Tables

Note 5 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		31-Mar-15		31-Dec-14
			$		$
	Raw materials		1,386		1,212
	Work in progress		797		309
	Finished goods		316		535
			2,499		2,056

Note_6_Accounts_Payable_and_Ac1

Note 6 - Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]		31-Mar-15		31-Dec-14
			$		$
	Trade accounts payable		1,816		1,624
	Employee related accounts payable and accrued liabilities		1,338		1,307
	Royalties		281		287
	Other accrued liabilities		1,230		649
			4,665		3,867

Note_7_Term_Loan_Tables

Note 7 - Term Loan (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Text Block [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]		31-Mar-15			31-Dec-14
			$			$
	Current portion of term loan		796			546
	Current portion of unamortized debt discount		(46	)		(52	)
	Current portion of term loan, net of debt discount		750			494
	Long-term portion of term loan		928			1,031
	Long-term portion of unamortized debt discount		(18	)		(27	)
	Long-term of term loan, net of debt discount		910			1,004
	Total		1,660			1,498
Schedule of Maturities of Long-term Debt [Table Text Block]	March 31,		$
	2016		796
	2017		796
	2018		132
	2019		-
	2020		-
	Thereafter		-
	Total		1,724

Note_8_Lease_Inducements_Table

Note 8 - Lease Inducements (Tables)	3 Months Ended
	Mar. 31, 2015
Other Liabilities and Financial Instruments Subject to Mandatory Redemption [Abstract]
Lease Inducements [Table Text Block]		31-Mar-15		31-Dec-14
			$		$
	Current Portion
	Rent-free inducement [i]		54		54
	Non-repayable leasehold improvement allowance [ii]		115		115
			169		169
	Repayable leasehold improvement allowance [iii]		474		461
	Total Current Portion		643		630
	Long-Term Portion
	Rent-free inducement [i]		371		385
	Non-repayable leasehold improvement allowance [ii]		783		812
			1,154		1,197
	Repayable leasehold improvement allowance [iii]		5,085		5,208
	Total Long-Term Portion		6,239		6,405
	Total		6,882		7,035

Note_9_Share_Capital_and_Addit1

Note 9 - Share Capital and Additional Paid-in Capital (Tables)	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three months ended March 31,		2015			2014
	Risk-free interest rates			0.98	%		2.06	%
	Expected dividend yield			0	%		0	%
	Expected life (in years)			6.1			5.8
	Expected volatility			121	%		126	%
	Fair value per stock option		$	0.8		$	1.31
Schedule of Share-based Compensation, Activity [Table Text Block]		Range of							Number of		Weighted average		Weighted average		Number of options		Weighted
		exercise price							shares under		remaining		exercise		currently		average exercise
									option		contractual life		price		exercisable		price
		$							#		(years)			$	#			$
		0.88				-	0.92			198,483		9.86		0.91		-		-
		1.02				-	1.60			288,302		8.21		4.46		178,067		1.41
							2.20			388,131		7.03		2.2		355,702		2.2
		3.00				-	3.10			176,243		7.97		3.09		162,375		3.1
		6.80				-	8.20			1,824		0.87		7.7		1,496		7.89
		0.88				-	8.20			1,052,983		8.03		1.91		697,640		2.22
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Number of optioned			Weighted average
			common shares			exercise price
			#				$
	Balance, December 31, 2014			1,007,629			1.99
	Options granted			128,793			0.92
	Options forfeited			(83,439	)		1.33
	Balance, March 31, 2015			1,052,983			1.91
Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]			Number			Weighted average
			of RSUs			exercise price
			#				$
	Balance, December 31, 2014			136,348			1.39
	RSUs granted			63,582			0.92
	RSUs converted to common shares			(114,978	)		(1.27	)
	Balance, March 31, 2015			84,952			1.2
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	Three months ended March 31,		2015			2014
				$			$
	Cost of sales			8			9
	Research and development			11			12
	General and administrative			23			119
	Sales and marketing			13			11
				55			151
Estimated Fair Value of Warrants Issued, Valuation Assumptions [Table Text Block]	As at March 31,		2015			2014
	Risk-free interest rates			0.5	%		1.07	%
	Expected dividend yield			0	%		0	%
	Expected life (in years)			1.75			2.75
	Expected volatility			102	%		139	%
	Fair value of warrant		$	0.0139		$	0.0629

Note_12_Segmented_Information_

Note 12 - Segmented Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	Three months ended March 31,	2015		2014
			$		$
	China		2,378		1,525
	United States		254		210
	Europe		200		428
	Asia (excluding China)		152		155
	Canada		7		4
	Other		280		237
	Total		3,271		2,559
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three months ended March 31,	2015		2014
			$		$
	Cardiovascular		3,089		2,438
	Infectious Diseases		49		69
	Biodefense products		55		44
	West Nile Virus (Environmental)		78		8
	Total		3,271		2,559

Note_2_Basis_of_Presentation_a1

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details)

3 Months Ended

12 Months Ended

12 Months Ended

60 Months Ended

12 Months Ended

60 Months Ended

0 Months Ended

6 Months Ended

0 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Mar. 31, 2016

Dec. 31, 2020

Mar. 31, 2015

Mar. 31, 2016

Dec. 31, 2020

Oct. 22, 2014

Mar. 31, 2015

Feb. 11, 2014

Dec. 15, 2014

CAD

CAD

CAD

CAD

Scenario, Forecast [Member]

Scenario, Forecast [Member]

Warrant [Member]

Development Milestone Payments [Member]

Revenue Based Payments [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Development Milestone Payments [Member]

Revenue Based Payments [Member]

CAD

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

USD ($)

USD ($)

USD ($)

USD ($)

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

Hangzhou Joinstar Biomedical Co. Ltd. [Member]

USD ($)

USD ($)

Note 2 - Basis of Presentation and Going Concern Uncertainty (Details) [Line Items]

Net Income (Loss) Attributable to Parent

-1,100,000

-1,523,000

-2,090,000

Net Cash Provided by (Used in) Operating Activities

-1,327,000

-272,000

Cash and Cash Equivalents, at Carrying Value

1,439,000

4,049,000

3,221,000

2,958,000

Retained Earnings (Accumulated Deficit)

-121,359,000

-120,259,000

Stockholders' Equity Attributable to Parent

-1,880,000

-894,000

-1,482,000

Working Capital Deficit

2,100,000

Derivative Liability, Current

1,194,000

1,249,000

1,200,000

Working Capital if Excluding Warrant Liability

951,000

Cash Proceeds from Technology Development Agreement (in Dollars)

2,130,000

1,280,000

1,640,000

Revenue Recognition, Milestone Method, Eligible to Receive (in Dollars)

2,160,000

Development Period

12 months

Commercialization Period

5 years

Term Loan, Maximum Borrowing Capacity (in Dollars)

2,500,000

Proceeds from Bank Debt (in Dollars)

1,500,000

Debt Instrument, Face Amount (in Dollars)

$1,400,000

Final Payment, Percentage of Principal

4.00%

Note_4_Fair_Value_Measurements2

Note 4 - Fair Value Measurements (Details) (CAD)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Note 4 - Fair Value Measurements (Details) [Line Items]
Fair Value Inputs, Discount Rate	11.00%
Derivative Liability, Current	1,194,000	1,249,000
Pro Forma [Member] | Warrant [Member]
Note 4 - Fair Value Measurements (Details) [Line Items]
Fair Value Measurement, Liability, Impact of 5 Percent Change in Volatility	90,000	82,000
Warrant [Member]
Note 4 - Fair Value Measurements (Details) [Line Items]
Derivative Liability, Current	1,200,000

Note_4_Fair_Value_Measurements3

Note 4 - Fair Value Measurements (Details) - Financial Instrument Carried at Fair Value (CAD)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant Liability	1,194	1,249
Fair Value, Inputs, Level 3 [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Warrant Liability	1,194

Note_4_Fair_Value_Measurements4

Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities (CAD)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2013
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability	1,249
Warrant Liability	-55	161
Warrant Liability	1,194
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability			1,249
Warrant Liability	-55
Warrant Liability	1,194		1,249
Fair Value, Inputs, Level 3 [Member]
Note 4 - Fair Value Measurements (Details) - Changes in Fair Value of the Level 3 Financial Liabilities [Line Items]
Warrant Liability	1,194

Note_4_Fair_Value_Measurements5

Note 4 - Fair Value Measurements (Details) - Quantitative Information about Unobservable Inputs (Warrant [Member])	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Warrant [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Warrant Liability	Option Model
Warrant Liability	102.00%	106.00%

Note_5_Inventories_Details

Note 5 - Inventories (Details) (CAD)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Note 5 - Inventories (Details) [Line Items]
Inventory Write-down	67,000	64,000
Expired and Damaged [Member]
Note 5 - Inventories (Details) [Line Items]
Inventory Valuation Reserves	129,000		135,000

Note_5_Inventories_Details_Inv

Note 5 - Inventories (Details) - Inventory (CAD)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory [Abstract]
Raw materials	1,386	1,212
Work in progress	797	309
Finished goods	316	535
	2,499	2,056

Note_6_Accounts_Payable_and_Ac2

Note 6 - Accounts Payable and Accrued Liabilities (Details) (Additions to PPE [Member], CAD)	Mar. 31, 2015
Additions to PPE [Member]
Note 6 - Accounts Payable and Accrued Liabilities (Details) [Line Items]
Accrued Liabilities and Other Liabilities	65,000

Note_6_Accounts_Payable_and_Ac3

Note 6 - Accounts Payable and Accrued Liabilities (Details) - Accounts Payable and Accrued Liabilities (CAD)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Accounts Payable and Accrued Liabilities [Abstract]
Trade accounts payable	1,816	1,624
Employee related accounts payable and accrued liabilities	1,338	1,307
Royalties	281	287
Other accrued liabilities	1,230	649
	4,665	3,867

Note_7_Term_Loan_Details

Note 7 - Term Loan (Details)

3 Months Ended

10 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2015

Mar. 31, 2014

Dec. 15, 2014

Dec. 15, 2014

Dec. 15, 2014

Feb. 11, 2014

Feb. 11, 2014

Mar. 31, 2015

Mar. 31, 2014

Dec. 15, 2014

Dec. 15, 2014

Feb. 11, 2014

CAD

CAD

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Silicon Valley Bank [Member]

Minimum [Member]

Maximum [Member]

CAD

Prime Rate [Member]

USD ($)

CAD

CAD

USD ($)

CAD

CAD

CAD

Note 7 - Term Loan (Details) [Line Items]

Term Loan, Maximum Borrowing Capacity (in Dollars)

$2,500,000

Debt Instrument, Basis Spread on Variable Rate

2.50%

Debt Instrument, Periodic Payment, Number of Installments

26

26

32

Debt Instrument, Face Amount (in Dollars)

1,400,000

Final Payment, Percentage of Principal

4.00%

4.00%

Class of Warrant or Right, Issued During Period (in Shares)

107,701

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

1

1.831

Fair Value Assumptions, Expected Term

10 years

Fair Value of Warrant

113,000

Deferred Finance Costs, Net

233,000

Amortization of Financing Costs

26,000

13,000

26,000

13,000

Amortization of Debt Discount (Premium)

15,000

5,000

15,000

5,000

Note_7_Term_Loan_Details_Term_

Note 7 - Term Loan (Details) - Term Loan Componnets (CAD)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Term Loan Componnets [Abstract]
Current portion of term loan	796	546
Current portion of unamortized debt discount	-46	-52
Current portion of term loan, net of debt discount	750	494
Long-term portion of term loan	928	1,031
Long-term portion of unamortized debt discount	-18	-27
Long-term of term loan, net of debt discount	910	1,004
Total	1,660	1,498

Note_7_Term_Loan_Details_Futur

Note 7 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) (Term Loan [Member], CAD)	Mar. 31, 2015
In Thousands, unless otherwise specified
Term Loan [Member]
Note 7 - Term Loan (Details) - Future Principal Payments for Term Loan (Incomplete) [Line Items]
2016	796
2017	796
2018	132
2019	0
2020	0
Thereafter	0
Total	1,724

Note_8_Lease_Inducements_Detai

Note 8 - Lease Inducements (Details) (CAD)	3 Months Ended		181 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Apr. 30, 2023
Note 8 - Lease Inducements (Details) [Line Items]
Interest Expense	235,000	197,000
Lease Incentive One [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee	14,000	14,000
Lease Incentive Two [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee	29,000	29,000
Allowance for Leasehold Improvement, Non-repayable			1,700,000
Lease Incentive Three [Member] | Monthly [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Allowance for Leasehold Improvement, Repayable			89,000
Lease Incentive Three [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Amortization of Lease Incentives, Lessee	110,000	89,000
Allowance for Leasehold Improvement, Repayable			7,800,000
Interest Expense	155,000	176,000
Letter of Credit [Member]
Note 8 - Lease Inducements (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	871,000
Line of Credit Facility, Collateral			$871,000

Note_8_Lease_Inducements_Detai1

Note 8 - Lease Inducements (Details) - Summary of Lease Inducements (CAD)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Current Portion
Lease Incentive Payable, Current	169		169
Repayable leasehold improvement allowance [iii]	474	[1]	461	[1]
Total Current Portion	643		630
Long-Term Portion
Lease Incentive Payable, Noncurrent	1,154		1,197
Repayable leasehold improvement allowance [iii]	5,085	[1]	5,208	[1]
Total Long-Term Portion	6,239		6,405
Total	6,882		7,035
Rent-free Inducement [Member]
Current Portion
Lease Incentive Payable, Current	54	[2]	54	[2]
Long-Term Portion
Lease Incentive Payable, Noncurrent	371	[2]	385	[2]
Repayable Leasehold Improvement Allowance [Member]
Current Portion
Lease Incentive Payable, Current	115	[3]	115	[3]
Long-Term Portion
Lease Incentive Payable, Noncurrent	783	[3]	812	[3]
[1]	The Company received a repayable leasehold improvement for an amount of $7.8 million used for additional improvements to the facility. This lease inducement is being repaid over the term of the operating lease commencing February 1, 2008 at approximately $89,000 per month including interest calculated at an interest rate negotiated between the Company and the landlord. Principal repayments for the three month period ended March 31, 2015 amounted to $110,000 [2014 - $89,000]. Interest payments for the three month period ended March 31, 2015 amounted to $155,000 [2014 - $176,000].
[2]	In 2007, the Company entered into a long-term facility lease agreement that included an eight and one half month rent-free period from May 17, 2007 to February 1, 2008. The lease inducement benefit arising from the rent-free period is being amortized on a straight-line basis over the term of the operating lease as a reduction to rental expense. Amortization expense for the three month period ended March 31, 2015 amounted to $14,000 [2014 - $14,000].
[3]	The Company received a non-repayable allowance for an amount of $1.7 million for expenditures related to general upgrades to the facility. The lease inducement benefit arising from the non-repayable leasehold improvement allowance is being amortized on a straight-line basis over the balance of the term of the lease beginning April 1, 2008 as a reduction to rental expense. Amortization expense for the three month period ended March 31, 2015 amounted to $29,000 [2014 - $29,000].

Note_9_Share_Capital_and_Addit2

Note 9 - Share Capital and Additional Paid-in Capital (Details) (CAD)	0 Months Ended	3 Months Ended		12 Months Ended	0 Months Ended
	Sep. 03, 2008	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 12, 2014
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,974,907
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number		1,052,983		1,007,629
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		921,924
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)		483,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 219 days
Common Share Price $1.83 [Member] | Silicon Valley Bank [Member] | Warrant [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding		52,796
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		1.831
Common Share Price 1.00 [Member] | Silicon Valley Bank [Member] | Warrant [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding		54,905
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		1
Restricted Stock Units (RSUs) [Member] | Accounts Payable and Accrued Liabilities [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Value, Issued for Services (in Dollars)		59,000
Restricted Stock Units (RSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		246,863
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		161,911
Deferred Share Unit Plan (DSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		246,863
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		246,863
Warrant [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		86,865,691	86,810,786
Equity Option [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1,052,983	1,487,304
Restricted Stock Units (RSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		84,952	48,595
Related to 2011 Financing [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding		86,103,744
Agent Warrants [Member] | Common Stock [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding		17,689
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		2.45
Private Placement [Member] | Common Stock [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				1,800,000
Private Placement [Member] | Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Stock Issued During Period, Shares, New Issues					1,800,000
Sale of Stock, Price Per Share (in Dollars per share)					1.21
Stock Issued During Period Value Private Placement, Gross (in Dollars)					2,178,000
Common Stock [Member] | Private Placement [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding		636,557
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		3.58
Common Stock [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Outstanding		86,865,691
Warrant [Member] | Private Placement [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		1.492
Hangzhou Joinstar Biomedical Co. Ltd. [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) [Line Items]
Proceeds from Issuance of Private Placement (in Dollars)					2,024,000
Payments of Financing Costs (in Dollars)					154,000

Note_9_Share_Capital_and_Addit3

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Share-based Payment Award, Stock Options, Valuation Assumptions (CAD)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]
Risk-free interest rates	0.98%	2.06%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	6 years 36 days	5 years 292 days
Expected volatility	121.00%	126.00%
Fair value per stock option (in Dollars per share)	0.8	1.31

Note_9_Share_Capital_and_Addit4

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding (CAD)	3 Months Ended
	Mar. 31, 2015
Range One [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	0.88
Range of exercise price- upper	0.92
Number of shares under option (in Shares)	198,483
Weighted average remaining contractual life	9 years 313 days
Weighted average exercise price	0.91
Range Two [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	1.02
Range of exercise price- upper	1.6
Number of shares under option (in Shares)	288,302
Weighted average remaining contractual life	8 years 76 days
Weighted average exercise price	4.46
Number of options currently exercisable (in Shares)	178,067
Weighted average exercise price - exercisable	1.41
Range Three [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- upper	2.2
Number of shares under option (in Shares)	388,131
Weighted average remaining contractual life	7 years 10 days
Weighted average exercise price	2.2
Number of options currently exercisable (in Shares)	355,702
Weighted average exercise price - exercisable	2.2
Range Four [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	3
Range of exercise price- upper	3.1
Number of shares under option (in Shares)	176,243
Weighted average remaining contractual life	7 years 354 days
Weighted average exercise price	3.09
Number of options currently exercisable (in Shares)	162,375
Weighted average exercise price - exercisable	3.1
Range Five [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	6.8
Range of exercise price- upper	8.2
Number of shares under option (in Shares)	1,824
Weighted average remaining contractual life	317 days
Weighted average exercise price	7.7
Number of options currently exercisable (in Shares)	1,496
Weighted average exercise price - exercisable	7.89
Range Six [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Outstanding [Line Items]
Range of exercise price- lower	0.88
Range of exercise price- upper	8.2
Number of shares under option (in Shares)	1,052,983
Weighted average remaining contractual life	8 years 10 days
Weighted average exercise price	1.91
Number of options currently exercisable (in Shares)	697,640
Weighted average exercise price - exercisable	2.22

Note_9_Share_Capital_and_Addit5

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Stock Options, Activity (USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Stock Options, Activity [Abstract]
Balance, number of optioned common shares	1,052,983	1,007,629
Balance, weighted average exercise price	$1.91	$1.99
Options granted	128,793
Options granted	$0.92
Options forfeited	-83,439
Options forfeited	$1.33

Note_9_Share_Capital_and_Addit6

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan (Restricted Stock Units (RSUs) [Member], CAD)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Restricted Share Unit Plan [Line Items]
Balance	84,952	136,348
Balance, weighted average exercise price	1.2	1.39
RSUs granted	63,582
RSUs granted	0.92
RSUs converted to common shares	-114,978
RSUs converted to common shares	-1.27

Note_9_Share_Capital_and_Addit7

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Allocation of Stock-based Compensation, by Type of Cost (CAD)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	55	151
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	8	9
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	11	12
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	23	119
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share based compensation expense	13	11

Note_9_Share_Capital_and_Addit8

Note 9 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued (Warrant [Member], CAD)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Warrant [Member]
Note 9 - Share Capital and Additional Paid-in Capital (Details) - Estimated Fair Value of Warrants Issued [Line Items]
Risk-free interest rates	0.50%	1.07%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	1 year 9 months	2 years 9 months
Expected volatility	102.00%	139.00%
Fair value of warrant (in Dollars)	0.0139	0.0629

Note_10_Related_Party_Transact1

Note 10 - Related Party Transactions (Details)	3 Months Ended	0 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2015	Oct. 22, 2014	Mar. 31, 2015	Dec. 31, 2014
	CAD	Hangzhou Joinstar Biomedical Co. Ltd. [Member]	Hangzhou Joinstar Biomedical Co. Ltd. [Member]	Hangzhou Joinstar Biomedical Co. Ltd. [Member]
		USD ($)	USD ($)	CAD
Note 10 - Related Party Transactions (Details) [Line Items]
Cash Proceeds from Technology Development Agreement		$1,280,000	$1,640,000
Contracts Revenue	269,000			269,000

Note_11_Commitments_Details

Note 11 - Commitments (Details) (CAD)	3 Months Ended		24 Months Ended	97 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Jun. 30, 2007	Jan. 31, 2023
Note 11 - Commitments (Details) [Line Items]
Royalty Expense			2,000,000
Operating Leases, Rent Expense, Net	209,000	203,000
Purchase Obligation	2,900,000
Purchase Obligation, Future Minimum Payments, Remainder of Fiscal Year	2,200,000
West Nile Virus [Member]
Note 11 - Commitments (Details) [Line Items]
Royalty Expense	8,000
Operation Facility [Member]
Note 11 - Commitments (Details) [Line Items]
Area of Real Estate Property (in Square Feet)	46,000
Operating Lease, Monthly Payments				173,000
Office in China [Member]
Note 11 - Commitments (Details) [Line Items]
Operating Lease, Monthly Payments	8,000
Developed Technology Rights [Member]
Note 11 - Commitments (Details) [Line Items]
Royalty Expense	217,000	117,000

Note_12_Segmented_Information_1

Note 12 - Segmented Information (Details) (CAD)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
One Customer [Member] | Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage	72.00%
One Customer [Member]
Note 12 - Segmented Information (Details) [Line Items]
Revenues (in Dollars)	2.4
Three Customers [Member] | Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		74.00%
Three Customers [Member]
Note 12 - Segmented Information (Details) [Line Items]
Revenues (in Dollars)		1.9
Customer One [Member] | Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		40.00%
Customer Two [Member] | Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		19.00%
Customer Three [Member] | Customer Concentration Risk [Member] | Sales Revenue, Goods, Net [Member]
Note 12 - Segmented Information (Details) [Line Items]
Concentration Risk, Percentage		14.00%

Note_12_Segmented_Information_2

Note 12 - Segmented Information (Details) - Product Sales by Customer Location (CAD)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	3,271	2,559
CHINA
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	2,378	1,525
UNITED STATES
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	254	210
Europe [Member]
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	200	428
Asia (excluding China) [Member]
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	152	155
CANADA
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	7	4
Segment, Geographical, Groups of Countries, Group Three [Member]
Note 12 - Segmented Information (Details) - Product Sales by Customer Location [Line Items]
Product sales	280	237

Note_12_Segmented_Information_3

Note 12 - Segmented Information (Details) - Product Sales by Type of Product (CAD)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Product sales	3,271	2,559
Cardiovascular [Member]
Segment Reporting Information [Line Items]
Product sales	3,089	2,438
Infectious Diseases [Member]
Segment Reporting Information [Line Items]
Product sales	49	69
Bio-defense Products [Member]
Segment Reporting Information [Line Items]
Product sales	55	44
West Nile Virus [Member]
Segment Reporting Information [Line Items]
Product sales	78	8